Palasciano Giuseppe, Moschetta Antonio, Palmieri Vincenzo O, Grattagliano Ignazio, Iacobellis Gianluca, Portincasa Piero
Clinica Medica A. Murri, Department of Internal & Public Medicine, University of Bari, Bari, Italy.
Curr Pharm Des. 2007;13(21):2193-8. doi: 10.2174/138161207781039652.
Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
非酒精性脂肪性肝病（NAFLD）常与代谢综合征的特征相关，增加了发展为非酒精性脂肪性肝炎（NASH）的风险，后者是肝脂肪变性的炎症形式。流行病学数据证实，肥胖、糖尿病、高血压和高脂血症在NAFLD中很常见，并且由于纤维化进展风险增加而使预后恶化，最终导致肝硬化。最近的研究证实了代谢综合征与肝脂肪变性之间的密切关系，并进一步支持氧化应激和脂质过氧化的有害作用，这两种病理生理过程在这两种情况下均存在。对于代谢综合征过程中肝功能障碍的管理，迫切需要新的诊断工具、生活方式的改变以及有针对性的治疗措施。
